Active not recruiting
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)
I8J-MC-JYCA - ClinicalTrials.gov - NCT02791334
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
Active not recruiting
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)
I8J-MC-JYCA - ClinicalTrials.gov - NCT02791334
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have diagnosis of advanced solid tumor confirmed by histology or cytology - Participants entering the Phase 1a dose escalation must submit, if available, an archival tumor tissue sample
Participants participating ONLY in the Phase 1b expansion must submit tissue sample from either a newly obtained core or excisional biopsy of a tumor lesion or a recent (≤3 years since last documented progression of disease.) biopsy
Participants must NOT
Participant must not have a serious concomitant systemic disorder including HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids
Participant must not have a bowel obstruction or chronic diarrhea
Participant must not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
Participant must not have received a live vaccine within 30 days before the first dose of study treatment
Trial Summary
Conditions the trial is for
Solid Tumor, Lung Cancer
What the trial is testing?
LY3300054, Ramucirumab, Abemaciclib, Merestinib
Could I receive a Placebo?
no
Enrollment Goal
215
Trial Dates
June 2016 - December 2021
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have diagnosis of advanced solid tumor confirmed by histology or cytology - Participants entering the Phase 1a dose escalation must submit, if available, an archival tumor tissue sample
Participants participating ONLY in the Phase 1b expansion must submit tissue sample from either a newly obtained core or excisional biopsy of a tumor lesion or a recent (≤3 years since last documented progression of disease.) biopsy
Participants must NOT
Participant must not have a serious concomitant systemic disorder including HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids
Participant must not have a bowel obstruction or chronic diarrhea
Participant must not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
Participant must not have received a live vaccine within 30 days before the first dose of study treatment
Trial Summary
Conditions the trial is for
Solid Tumor, Lung Cancer
What the trial is testing?
LY3300054, Ramucirumab, Abemaciclib, Merestinib
Could I receive a Placebo?
no
Enrollment Goal
215
Trial Dates
June 2016 - December 2021
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
